Excess angiogenesis or neovascularization (NV) plays a key role in the pathophysiology of several ocular diseases such as retinopathy of prematurity, wet form of age-related macular degeneration (AMD), and diabetic retinopathy. 1 The angiogenesis is regulated by a large number of angiogenesis-related factors and determined by a relative balance between pro-and anti-angiogenic factors. 2 The angiogenesis-related factors form a well-coordinated and functional network of molecules affecting the angiogenesis process, 
and thus, an effective therapy may require targeting multiple components of the angiogenic pathway. Endothelial cells are involved in many aspects of vascular biology by producing different factors that regulate cell adhesion, cell proliferation, and vascular tone. 3 The signaling of vascular endothelial growth factor (VEGF) is one of the most potent pathways and is almost exclusively found in endothelial cells. Importantly, a large number of microRNAs (miRNAs) are responsible for angiogenesis and are expressed in endothelial cells. [4] [5] [6] miRNAs are a group of endogenous small noncoding regulatory RNAs (~22 nucleotides) silencing their target genes at the post-transcriptional level. 7, 8 Each miRNA regulates the expression of multiple protein-coding genes, and therefore, miRNA-based therapy provides the rationale basis for effective anti-angiogenic treatment. 9 The extracellular microvesicles (EVs) are biological effectors to influence various physiological and pathological functions of recipient cells. [10] [11] [12] We have demonstrated that EVs derived from apoptotic human T lymphocytes (LMPs) possess strong anti-angiogenic properties in in vivo corneal neovascularization and tumor neovascularization 13, 14 and limit neovascularization of oxygen-induced retinopathy (OIR) and neovascularization in a laser-induced murine choroidal neovascularization (CNV) model. [13] [14] [15] [16] [17] [18] Nonetheless, the potent anti-angiogenic components of LMPs have not been well explored. Selective disposal of some miRNAs in EVs has been suggested to mediate both short-range and distant communication between various cells and could impact diverse physiological and pathological processes. [19] [20] [21] The main goal of this study was to investigate the miRNAs that mediate the anti-angiogenic effect of LMPs.
| ME THODOLOGY

| Cellculture
Human retinal endothelial cells (HRECs) were obtained from Applied Cell Biology Research Institute and cultured as recommended.
Human umbilical vein endothelial cell lines (HUVEC) were purchased from ATCC and were maintained according to standard procedures.
| LMPsproduction
Human CEM T cells were purchased from ATCC and grown in X-VIVO medium (Cambrex). Lymphocyte-derived microparticles were generated and characterized as described previously. 
| RNAisolationfromLMPs
RNAs were isolated from LMPs using the miRNeasy Mini Kit (Qiagen) according to the manufacturer's protocol. Quality threshold and the concentrations were determined using NanoDrop ND-1000 (NanoDrop Technologies). High RNA quality of isolated RNA was confirmed for all samples using the BioAnalyzer 2100 (Agilent Technologies). 
| Expressionprofiling-IlluminaBeadChips
| Proliferationassay
Human retinal endothelial cells (HRECs) were transfected with 20 nmol/L of miR-181a inhibitor (hsa-miR-181a-5p inhibitor, Thermo
Fisher Scientific) via liposomes CLS-3 (8 μmol/L, a gift from Dr. Jeanne
Leblond-Chain, University of Montreal) before incubation with LMPs (10 μg/mL). After 48 hours of treatment, cell proliferation was evaluated by [ 3 H]-thymidine incorporation assay as we described previously. 13 In a different experiment, endothelial cells were transfected with indicated concentrations of mirVana™ miRNA mimics (10, 25, 40 , and 50 nmol/L) for 48 hours. The mimics of miR-181a-5p (hsa-181a-5p) and miRscr (negative control #1) were purchased from Thermo Fisher
Scientific. The cells were subjected to a proliferation assay.
| Apoptosisassay
Cells were seeded in 96-well plate. The next day, cells were exposed 
| Endothelialcelltubeformationassay
The endothelial cell tube formation assay was performed as described. 22 The mimic of hsa-miR-181a-5p (mirVana ® miRNA mimic), and mirVana™ miRNA mimic negative control were purchased from Thermo Fisher Scientific. HRECs were transfected with 50 nmol/L mimic of miR-181a-5p or miRscr. Twenty-four hours later, cells were seeded on Matrigel™ (BD Biosciences). The images were taken after 17-hour seeding using fluorescence microscopy (Eclipse E800, Nikon Corp).
| Treatmentofchoroidalexplantsand measurementofneovascularization
The human RPE-removed choroidal explants were prepared according to our previously described procedure. 16, 17 Briefly, choroidal explants were cultured in growth factor-reduced basement membrane matrix 5 days. On day 6, explants were transduced with lenticontrol and lenti-miR-181a-5p (10 6 U/mL) for 72 hours. Photographs of individual explants were taken at the end of treatment, and the neovessel areas were determined.
| Oxygen-inducedretinopathymousemodel (OIR)andretinaNVquantification
The OIR model is generated based on the established method. 23 Briefly, the postnatal day P12 OIR mice (n = 7 mice) received intravitreal injections of 1 μL of 10 10 U/mL of lenti-miR-181a-5p in 1 eye and lenti-control in the contralateral eye respectively. At P17, retinal flatmounts were prepared as described previously. 24 Of note, to avoid the influence of postnatal body weight and postnatal weight gain on the severity of retinal NV in OIR model, 25, 26 we measured mice body weight before and after lentivirus treatments. The P12 OIR mice with body weight lower than 5 g or over 7 g were discarded, and the mice at P17 with body weights between 5 and 7.5 g were kept for retinal NV analysis. Vessels in flat-mounted retinas were stained with red fluorescent isolectin B4, and the area of neovascular tufts was measured as described. 27 Neovascularizations were quantified by comparing the number of pixels in the neovascular tuft areas with the total number of pixels in the retina using the SWIFT-NV method.
24,28
| QuantitativeRT-PCR
Total RNA was extracted from HRECs using an RNA extraction kit (Qiagen). Synthesis of cDNAs and quantitative analysis of gene expression were performed as we described previously. 29 β-actin was used as internal control. PCR primers targeting human MAPK1, Bcl-2, VEGF, and β-actin were synthesized by Alpha DNA (Montreal, Canada) as follows:
MAPK1: forward 5′-GGCCCCTGAAAGAATAAACCC-3′, reverse 5′-CGAAGGATGGCCAACTCAATC-3′; Bcl-2: forward 5′-GGTGAAC TGGGGGAGGATTG-3′, reverse 5′-GTGCCGGTTCAGGTACTCAG-3′;
VEGF: forward 5′-CTACCTCCACCATGCCAAGT-3′, reverse 5′-GCAG TAGCTGCGCTGATAGA-3′; β-actin: forward 5′-CTGCGGCATTCA CGAAACTAC-3′, reverse 5′-ATCTCTTTCTGCATCCTGTCCG-3′. The method of analyzing the expression of mouse VEGFα and 18s in OIR mice retina was described previously. 16 
| Statisticalanalysis
All experiments were repeated independently at least 3 times in duplicate or triplicate. Values are presented as means ± SEM. Statically significant differences between 2 groups were analyzed by Student's t test. One-way ANOVA followed by post hoc Bonferroni tests was performed for comparison among means. Statistical significance was set at P < .05.
| RE SULTS
| InhibitionofmiR-181asignificantlyattenuated theeffectofLMPsonHRECproliferation
We have previously reported that LMPs exert a strong inhibitory effect on proliferation of endothelial and cancer cells. 13, 15, 30 We have also demonstrated that LMPs significantly reduced the proliferation of human retinal endothelial cell (HREC) in a dose-dependent manner. 15 As a first step in identifying miRNAs that are enriched in LMPs, we isolated the total RNAs from LMPs and performed RNAs sequence. The resulting data suggested that miRNAs are selectively incorporated into LMPs in which miR-181a is one of the most abundant miRNAs (Table 1) . Thus, we speculated that miR-181a may play a role in mediating the effect of LMPs on endothelial cells. To prove this hypothesis, we used the inhibitor of miR-181a to block the activity of miR-181a when HRECs were incubated with LMPs.
The results of cell proliferation assay suggested that the inhibitor of miR-181a significantly, not dramatically, attenuated the effect of LMPs ( Figure 1A ). The same phenomenon was observed in the proliferation assay of human umbilical vein endothelial cells (HUVECs; Figure 1B ). The read counts of mir-181a-1 and mir-181a-2 in 3 LMPs and their means were indicated in bold. 
| miR-181ainhibitedendothelialcell proliferation
The synthetic mimic of miR-181a-5p was used to test antiproliferative activity in HREC. The miR-181a-5p inhibited cell proliferation in a dose-dependent manner, producing up to 50% inhibition compared to a negative control miRNA (miRscr; Figure 2A ). miR-181a-5p
was also overexpressed in the human umbilical vein endothelial cell (HUVEC) with lentiviral vector (lenti-miR-181a-5p), and cell growth was assessed by MTT assay. The cell growth of the HUVECs infected with lenti-miR-181a-5p was reduced in a dose-dependent manner ( Figure 2B ). Given the significant reduced cell growth by miR-181a, it is plausible to question whether miR-181a-5p affects cell apoptosis.
To address this question, we performed the cell apoptosis assay on the HRECs overexpressing miR-181a by lentiviral vector. The lentimiR-181-5p at the MOI of 10 did not significantly induce HREC death 
| miR-181ainhibitedangiogenesisinvitroand exvivo
We performed an endothelial cell tube formation assay to assess the anti-angiogenic effect of miR-181a-5p in vitro. HREC transfected with mimic of miR-181a-5p showed dramatically decreased tube formation: a 70% decrease, compared to HREC transfected with miRscr mimic ( Figure 3A,B) . We also investigated the effects of miR-181a on neovessel sprouting from cultured human choroidal explants. The human choroidal explants were transduced with lenti-control and lenti-miR181a-5p. The neovascularized areas were strongly suppressed by miR181a, with a reduction of 84.1 ± 6.6%, compared to the control group ( Figure 3C,D) .
F I G U R E 3 miR-181a inhibited angiogenesis in vitro and ex vivo. A, Representative images of tube formation assay after HREC transfected with mimic of 50 nmol/L of miR-181a-5p or miRscr. Twenty-four hours after the transfection, HRECs were seeded on Matrigel. The images were taken after 17 hours of seeding using fluorescence microscopy. B, The tube formation was quantified by calculating the cumulative length of the tube of each image. Data are plotted as mean ± SE, *** P < .0001 vs miRscr. C, Representative images of human choroidal angiogenesis. The human choroidal explants were cultured in normal medium for 5 days for neovessel growth and then tranduced with lenti-control and lenti-miR-181a-5p. The images were taken 3 days after lentivirus infections. D, The neovascularized areas in each condition were calculated and presented as a percentage of control (CTL, set as 100%). Data are plotted as mean ± SE, **P .011 vs lenticontrol 
| miR-181ainhibitsretinalneovascularization inthemousemodelofoxygen-inducedretinopathy
To extend our investigation of the in vivo effect of miR-181a, we used an oxygen-induced retinopathy mouse model (OIR, a wellestablished animal model of ischemia-induced retinal neovascularization). Along with the in vitro and ex vivo effects, intravitreal injections of lenti-miR-181a-5p significantly decreased the retinal neovascularization areas, by 52% compared to the lenti-control group ( Figure 4A,B) . In line with this observation, the retinal VEGF expression was significantly decreased in the miR-181a-treated OIR mice ( Figure 4C ).
| miR-181aalteredtheexpressionofangiogenic factorsinendothelialcells
To better understand how miR-181a produces its anti-angiogenic effect in endothelial cells, we performed quantitative PCR to analyze the expression of the target genes of miR-181a-5p in the HREC transduced with lenti-miR-181a-5p. These genes were selected based on the published papers [31] [32] [33] and database of TargetScanHuamn 7.1 (http://www.targetscan.org/), miRTarBase (http://mirtarbase.mbc.
nctu.edu.tw/). They are involved in endothelial biological processes associated with angiogenesis, such as the cell cycle, cell migration, cell growth, and proliferation. 33 They are the mitogen-activated protein kinase 1 (MAPK1), 32 B-cell lymphoma 2 (Bcl2), 31 and VEGF. 33 Compared to those in HRECs transduced with lenti-control, the mRNA levels of these genes were all significantly reduced by miR-181a-5p ( Figure 5 ).
| D ISCUSS I ON
There is mounting evidence that extracellular microvesicles (EVs) provide a means of intercellular communication both in physiological and pathological conditions, by local and systemic intercellular exchange of biological information. 34 Lymphocyte-derived microparticles are membrane-derived EVs derived from human apoptotic T cells. 13 The strong anti-angiogenic effect of LMPs has been demonstrated in vitro, ex vivo, as well as in several in vivo models. [13] [14] [15] It is well documented that EVs harbor a concentrated set of phospholipids, cytokines, proteins, RNAs, DNA, etc. and can influence diverse biological functions. 35 Since the discovery of miRNAs secreting within EVs (ex-miRNAs) in 2008, ex-miRNAs have been of interest to molecular biologists. 19, 20 Our RNA sequence analysis revealed for the first time that miR-181a is one of the most abundant ex-miRNAs in the LMPs. This finding is supported by the fact that miR-181a was found highly expressed in the thymus, the primary lymphoid organ where maturation of T lymphocytes occurs in the early stages of T-cell differentiation. 20, [36] [37] [38] [39] Even though enriched in LMPs, miR-181a is one of the hundred miRNAs expressed in LMPs. The inhibition of miRNA-181a caused only partial attenuation of the effect of LMPs (Figure 1 ), which suggested that miR-181a may not be the only active component. Lymphocyte-derived microparticles are heterogenic components containing lipids, proteins, DNAs, and RNAs in addition to miRNAs. 35 The strong anti-angiogenic effects of LMPs may result from the synergistic effects of many different components in LMPs, and thus, more in-depth studies are needed to explore the other active factors.
The members of the miR-181 family are evolutionarily conserved across almost all vertebrates, suggesting their functional importance. 37, 40 Numerous studies have reported the involvement of miR-181a in important cell functions such as growth, proliferation, death, survival, maintenance, vascular cell signaling, and blood vessel formation. 9 Recently, the roles of miR-181a in the regulation F I G U R E 4 miR-181a inhibited in vivo retinal neovascularization of oxygen-induced retinopathy (OIR) in mice. A, The images of retinal flatmounts from OIR mice were taken at postnatal day 17 (P17) after intravitreal injections at P12 with 1 μL of 10 10 U/mL of lenti-control or lenti-miR-181a-5p. B, Retinal surface area covered by tufts (neovascularized area) was measured and quantified as a percentage of the entire retinal area, and these values were presented as relative to the lenti-control group, which was set as 100%. **P .0027 vs lenti-control. C, Total RNAs were isolated from retina tissues of OIR mice at P17 and subjected to quantitative RT-PCR. VEGF values were normalized to values for β-actin mRNA and presented as percentages of lenti-control group. *P .035 vs control and miR-181a promotes tumor angiogenesis through directly targeting G-protein signaling 16 and consequently increasing CXC chemokine receptor 4 signaling. 45 Conversely, the anti-angiogenic property of miR-181a was identified from 2 independent studies. Ocular angiogenesis is a major cause of many ocular diseases and blindness. It is a significant contributing factor in diabetic retinopathy, exudative AMD, corneal neovascularization, retinopathy of prematurity, neovascular glaucoma, etc. The ocular expression of miR-181a has been studied in the mouse and in the human eye. In the mouse, miR-181a was identified as strongly expressed in the retina 48 ;
in the human eye, miR-181a was abundantly expressed in the retina and RPE/choroid tissues. 49 One in vitro study revealed that hypoxia increased the expression of miR-181a in choroidal endothelial cells and suggested an anti-angiogenic role of miR-181a through inhibiting cell migration and proliferation. 50 However, the role of miR-181a in pathophysiological angiogenesis in vivo has not been verified. Our current data generated from in vitro, ex vivo (choroidal neovascularization), and in vivo retinal neovascularization model (OIR), strongly support the anti-angiogenic role of miR-181a (Figures 2-5) . Of special note, we observed that the concentration is critical for the antiproliferation effect of miR-181a on endothelial cells, because the high dose of miR-181a (≥100 nmol/L of miR-181a-5p mimic) lost its effect on endothelial cell growth in vitro. Instead, endothelial cell growth was slightly increased, although not significant (P .372 vs control; Figure S1 ). Similar results were also observed in miR-181a-treated HUVECs, breast cancer cells (MCF-7, MDA-MB-231), retinoblastoma cells (Y-79), and glioblastoma cells (U87, Gl261) when the concentration of lenti-miR-181a is high (MOI ≥100; data not shown).The possible explanation is that miR-181a may target multiple mRNAs within a cell, which means miR-181a may be both an agonist and an antagonist of a pathway. Thus, the final effect of a miR-181a may depend on the transcriptome of the cell and the behavior of the targets as well.
In pathological conditions, there is an imbalance of proangiogenic and anti-angiogenic factors secreted by retinal endothelial cells, and the overexpression of VEGF plays an important role in the pathogenesis of ocular angiogenesis. 51 Recent studies have shown a reciprocity relationship between the angiogenic activity of VEGF and Bcl2; the latter is an antioxidant and anti-apoptotic resident mitochondrial protein. 52 Nor et al 53 58 Although the combination of TargetScan and miRNAmap software does not predict that VEGF is the putative target gene of miR-181a, a correlation between the overexpression of miR-181a and VEGF was reported. 33 In keeping with this observation, we also showed that the expression of Bcl-2 and VEGF was significantly downregulated by overexpression of miR-181a in HRECs ( Figure 5 ).
In addition to Bcl2, direct targeting of miR-181a to MAPK1 (also named ERK5 or BMK1) was confirmed by luciferase reporter gene assays. 32 MAPK1 is expressed in a variety of tissues and its transcript is abundant in heart, placenta, lung, kidney, skeletal muscle, and endothelial cells. 59, 60 It can be activated by a range of growth factors, cytokines, and cellular stresses. MAPK1-deficient mice and targeted deletion of MAPK1 in an adult mice model suggested an important role of MAPK1 in controlling angiogenesis. [61] [62] [63] As VEGF functions as a potent activator for MAPK1 in endothelial cells, MAPK1 is likely responsible for transmitting VEGF-dependent antiapoptotic signals. 63 One study also indicated the role of MAPK1 signaling in diabetic angiopathy. 64 Herein, we observed that in HRECs, overexpression of miR-181a strongly inhibited MAPK1 In conclusion, we demonstrated for the first time that miR-181a exerts a strong antineovascularization effect in ocular angiogenesis models; in addition, miR-181a specifically targeted a set of angiogenic and cell growth-related genes. These data suggest that miR181a may be developed as a new therapeutic strategy for treating ocular angiogenesis-related diseases.
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